[186 Pages Report] The Travel Vaccines Market size was estimated at USD 8.26 billion in 2023 and expected to reach USD 9.09 billion in 2024, at a CAGR 10.06% to reach USD 16.18 billion by 2030.
The travel vaccines market encompasses the production, distribution, and administration of immunizations recommended or required for international travelers based on specific regional disease risk exposures. The ongoing growth in the travel vaccines market is primarily driven by increased international travel, rising awareness about vaccine-preventable diseases, and governmental travel regulations mandating certain vaccines for entry. Additionally, the expansion of the global tourism industry and proactive health measures by international travelers fuel the demand for travel vaccines. Technological advancements in vaccine storage and stability contribute to market growth by enabling wider vaccine accessibility and distribution. The major challenges affecting the growth of the travel vaccines market include high costs associated with vaccine development and strict regulatory requirements leading to prolonged approval times. Additionally, the limited shelf life of vaccines, cold chain logistics requirements, and vaccine hesitancy among specific traveler demographics further impede market growth. Emerging market opportunities include developing vaccines against evolving infectious disease threats and expanding the existing travel vaccine portfolio to include neglected tropical diseases. An increase in public-private partnerships for vaccine research and development and the incorporation of digital health technologies for personalized travel health advisories and vaccine reminders represent significant prospects for industry expansion.
In the Americas, the United States and Canada represent significant markets for travel vaccines, driven by high outbound travel rates and robust healthcare infrastructure. Consumer behavior shows a high degree of awareness and preparedness for travel health, leading to a steadfast demand for vaccines against diseases such as Yellow Fever, Typhoid, and Hepatitis A and B. The European Union exhibits a robust travel vaccine market due to well-established healthcare systems and high travel frequency to regions with vaccine-preventable diseases. The EU's streamlined regulatory framework fosters a conducive environment for introducing new vaccines. The Middle East & Africa region presents a varied landscape for travel vaccines, with the Gulf Cooperation Council countries showing growing demand due to increasing travel and healthcare investments. The Asia Pacific region is witnessing rapid growth in the travel vaccine market, with China, Japan, and India leading the way for market expansion. Notably, China and India invest heavily in vaccine R&D to become self-sufficient in vaccine production. Japan's market is distinguished by high consumer awareness and advanced vaccine technology, supported by government-led immunization campaigns.
The market dynamics represent an ever-changing landscape of the Travel Vaccines Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
- Market Drivers
- Increasing Popularity of International Tourism
- Growing Prevalence of Infectious Diseases and Development of Combination Vaccines
- Recent Investments and Improvement in Cold Chain Storage Infrastructure
- Market Restraints
- Limited Awareness Amongst Travelers
- Market Opportunities
- Innovations in Novel Vaccine Technologies and Advancements
- Government and Organizational Funding and Initiatives for Immunization and Vaccine Development
- Market Challenges
- Issues Related to Vaccine Handling and Storage
Type: Advancements in DNA vaccines to induce immune response
Attenuated vaccines utilize a weakened form of the germ that causes a disease. Attenuated vaccines are highly effective in eliciting strong and long-lasting immune responses. Conjugate vaccines are designed to combat bacteria with polysaccharide outer coatings. By linking antigens or toxoids from a microbe that the immune system can recognize to the polysaccharides, conjugate vaccines improve the body's immune response to the bacterium. DNA vaccines represent a cutting-edge approach by directly injecting genetically engineered DNA so cells can produce an antigen and induce an immune response. Inactive vaccines use the killed version of the germ that causes a disease and are safer than live vaccines, especially for people with weakened immune systems, but may require multiple doses to maintain immunity. Recombinant vector vaccines use a virus or a bacterium to introduce microbial DNA to body cells and are sophisticated in design and capable of inducing strong immune responses. Subunit vaccines include only the essential antigens and not all other molecules of the microbe and have a lower risk of side effects but may require adjuvants to enhance the immune response. Toxoid vaccines are used against bacteria that produce toxins in the body and are made by inactivating the toxins produced by the bacteria, which in turn induces an immune response.
Disease: Need based preference for hepatitis vaccines among travelers
DPT vaccines are primarily recommended for young children, but booster shots are advised for adults traveling to areas where diphtheria and pertussis (whooping cough) are still prevalent. Hepatitis is recommended for most travelers, especially those visiting regions with higher rates of Hepatitis A infection such as Asia, Africa, and Central and South America. Japanese encephalitis is advised for travelers staying for extended periods in endemic areas, especially in rural Asia. The meningococcal vaccine is essential for travelers to sub-Saharan Africa during the dry season and for pilgrims to the Hajj in Saudi Arabia. Rabies vaccine is recommended for travelers involved in outdoor activities in areas where rabies is a risk or for those traveling to remote locations where medical care is difficult to access. Varicella (Chickenpox) is essential for non-immune travelers, particularly young adults and healthcare professionals. Yellow fever is critical for travelers to endemic regions in Africa and South America.
The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Travel Vaccines Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Travel Vaccines Market.
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Travel Vaccines Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.
The value chain of the Travel Vaccines Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.
The pricing analysis comprehensively evaluates how a product or service is priced within the Travel Vaccines Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Travel Vaccines Market.
The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Travel Vaccines Market.
The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Travel Vaccines Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.
The trade analysis of the Travel Vaccines Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.
The regulatory framework analysis for the Travel Vaccines Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Travel Vaccines Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Travel Vaccines Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
India's First Indigenously Developed Hepatitis A Vaccine Launched In Hyderabad
The Indian Immunologicals Limited (IIL) has launched Havisure, the nation’s first indigenously developed vaccine against Hepatitis A. This highly contagious liver infection, primarily transmitted through the fecal-oral route via contaminated food or water, represents a substantial public health concern. Through rigorous clinical testing across eight centers, Havisure has demonstrated its safety and efficacy, showcasing results on par with the leading global vaccines [Published On: 2024-01-20]
FDA Approves PENBRAYA, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
Pfizer Inc. has achieved a significant milestone in public health with the U.S. Food and Drug Administration (FDA)'s approval of PENBRAYA, the inaugural pentavalent vaccine offering comprehensive protection against the predominant serogroups (A, B, C, W, and Y) responsible for causing meningococcal disease among adolescents and young adults aged 10 through 25. This innovative vaccine merges the strengths of Trumenba and Nimenrix, targeting the five key serogroups linked to the majority of invasive meningococcal disease (IMD) instances globally. [Published On: 2023-10-20]
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
Pfizer Inc. and BioNTech SE have announced the approval from the U.S. Food and Drug Administration (FDA) for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine, tailored for the 2023-2024 flu season. This approval encompasses a supplemental Biologics License for those aged 12 and older, alongside an emergency use authorization for ages 6 months to 11 years. This updated vaccine, recommended for a single dose in individuals 5 years and up—with particular dosing guidelines for children under 5—aims to fortify protection against the evolving COVID-19 variants, especially the predominant Omicron XBB-related sublineages. [Published On: 2023-09-11]
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Travel Vaccines Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
The report delves into recent significant developments in the Travel Vaccines Market, highlighting leading vendors and their innovative profiles. These include Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Cadila Pharmaceuticals Limited, Shenzhen Kangtai Biological Products Co., Ltd., Novartis AG, Dynavax Technologies Corporation, CSL Limited, Emergent BioSolutions Inc., Bio-Med (P) Limited, Bharat Biotech Ltd., Indian Immunologicals Ltd., Dano Vaccines & Biologicals Private Limited, Bavarian Nordic A/S, Johnson & Johnson Services, Inc, Pfizer Inc., Incepta Pharmaceuticals Ltd., GlaxoSmithKline PLC, Serum Institute of India Pvt. Ltd., Abbott Laboratories, AstraZeneca PLC, Walvax Biotechnology Co., Ltd., Bio-Manguinhos, Valneva SE, Sanofi S.A., and Biological E Limited.
This research report categorizes the Travel Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Type
- Attenuated Vaccines
- Conjugate Vaccines
- DNA Vaccines
- Inactive Vaccines
- Recombinant Vector Vaccines
- Subunit Vaccines
- Toxoid Vaccines
- Disease
- DPT
- Hepatitis A
- Hepatitis B
- Japanese Encephalitis
- Measles and Mumps
- Meningococcal
- Rabies
- Typhoid
- Varicella
- Yellow Fever
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Travel Vaccines Market, by Type
- Travel Vaccines Market, by Disease
- Americas Travel Vaccines Market
- Asia-Pacific Travel Vaccines Market
- Europe, Middle East & Africa Travel Vaccines Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 20]
- List of Tables [Total: 218]
- List of Companies Mentioned [Total: 25]
DNA Vaccines:
Traditional vaccines introduce a weakened or inactive form of a virus to the body, which escalates an immune response in the patient. However, recent breakthroughs in genetic engineering have led to a novel type of vaccine made of DNA strands. This approach introduces a harmless piece of genetic material into the body that can ultimately help create immunity to diseases like malaria, dengue, and Zika. These new DNA vaccines have been shown to be potentially less expensive, more efficient, and safer than traditional vaccines.
Microneedle Patches:
Getting vaccinated can be a stressful and painful experience for many, especially those with needle phobias. Microneedles are a new technology that replaces traditional injections with a skin patch that is covered with tiny needles that painlessly penetrate the epidermis. These patches have been tested for delivering vaccines against the flu and are currently being researched for many other vaccines, including those needed for travel. They have the potential to make vaccines easier, less painful, and more accessible for many people, particularly for those living in rural and low-income areas.
Adjuvants:
Adjuvants are substances added to vaccines that help them increase the body's immune response. They help the immune system recognize the vaccine as a dangerous infection, triggering a stronger and longer-lasting response. Adjuvants can help reduce the amount of vaccine required to achieve immunity and reduce side effects associated with vaccines. By using adjuvants, it is possible to enhance the efficacy of vaccines against existing and emerging pathogens, making them more effective for travel.
Temperature-Stable Vaccines:
One challenge with vaccines is keeping them stable during transport and storage. Traditional vaccines often need to be kept refrigerated or frozen, which can make them hard to transport safely and store in remote areas. In recent years, several vaccines have been developed that can survive at higher temperatures and do not require refrigeration. This means that vaccines will be more accessible in areas with limited electricity and transport infrastructure, making them suitable for use even in the most remote areas.
Novel Platform Technologies:
A novel platform technology refers to a new approach to developing vaccines that uses a common approach across diseases. This approach helps in the development of vaccines in a quicker and safer way. Some new platform technologies that are being developed for travel vaccine development include virus-like particles (VLP) vaccines, nucleic acid-based formulations, and viral-vectored vaccines. These technologies are not only faster to develop but also can be specific and safe for particular groups of people.
Traveling can be exciting; however, it can also pose health risks due to unfamiliar diseases. Novel vaccine technologies and advancements make traveling safer and provide tourists with protection against illnesses from regions they visit. These technologies include DNA-based formulations, microneedle patches, adjuvants for personalized immunity, temperature-stable vaccines, and novel platform technologies. Thanks to these advances, travelers can visit the most remote corners of the world with confidence, knowing that the latest innovations in travel vaccines are keeping them safe.
- How big is the Travel Vaccines Market?
- What is the Travel Vaccines Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?